Assets
Crypto Deposit
Fiat Deposit
Convert
Transfer
Withdraw
My vouchers
Fund history
Dashboard
Account Security
Identity verification
API Management
Transaction Report
Log out
Register
BTCC / BTCC Square / Global Cryptocurrency /
Vanda Pharmaceuticals’ BYSANTI Approval Sparks 44% Stock Surge

Vanda Pharmaceuticals’ BYSANTI Approval Sparks 44% Stock Surge

Author:
Global Cryptocurrency
Published:
2026-02-23 10:37:02
20
2
BTCCSquare news:

Vanda Pharmaceuticals Inc. (VNDA) shares rallied as much as 44% in after-hours trading following FDA approval of its novel antipsychotic drug BYSANTI. The New Chemical Entity designation grants patent protection until 2044, creating a nearly two-decade window without generic competition.

The milestone marks Vanda's second FDA approval within two months, following December 2025's NEREUS clearance. BYSANTI's accelerated approval timeline and upcoming Q3 2026 launch position the small-cap biotech for potential transformation. Depression trial results expected by year-end 2026 could further catalyze growth.

|Square

Get the BTCC app to start your crypto journey

Download on the App Store GEI IT ON Google Play

Get started today Scan to join our 100M+ users

Exchange for a better future

Products
Services
Guides
About Us
Terms & Agreement
Customer Service

Risk warning: Digital asset trading is an emerging industry with bright prospects, but it also comes with huge risks as it is a new market. The risk is especially high in leveraged trading since leverage magnifies profits and amplifies risks at the same time. Please make sure you have a thorough understanding of the industry, the leveraged trading models, and the rules of trading before opening a position. Additionally, we strongly recommend that you identify your risk tolerance and only accept the risks you are willing to take. All trading involves risks, so you must be cautious when entering the market.

The world’s longest-running cryptocurrency exchange since 2011 © 2011 - 2026 BTCC.com. All rights reserved

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.